Study on the role and mechanism of β4GalT1 both in vivo and in vitro glioma.

OBJECTIVE

To discuss the role and mechanism of β4GalT1 both in vivo and in vitro glioma, observe whether pathophysiological processes of glioma can be improved after β4GalT1 is knocked down, and study whether β4GalT1 plays a role in malignant biological processes of glioma by regulating the apoptosis and immune processes.

PATIENTS AND METHODS

Firstly, the distribution difference of β4GalT1 in tumor tissues and normal tissues was analyzed by Gene Expression Profiling Interactive Analysis (GEPIA) tumor analysis system to deduce the possible role of β4GalT1 in glioma. Secondly, whether the malignant degree of glioma was related to the expression of β4GalT1 and its immunity using human tumor tissues and blood lymphocyte subsets was analyzed. Thirdly, interfere lentivirus vector with β4GalT1 and knockdown β4GalT1 was analyzed to observe whether the malignant degree of glioma has changed. Fourthly, interfere lentivirus vector with recombinant β4GalT protein and β4GalT1 was analyzed to verify the effect of β4GalT in vitro test. Fifth, interfere lentivirus vector with recombinant β4GalT protein and β4GalT1 was analyzed to verify effect of β4GalT in vivo test. Finally, we discuss whether β4GalT is involved in the biological process of glioma through inflammatory reaction.

RESULTS

In the GEPIA tumor analysis system, the expression in tumor was significantly higher than that in normal tissues. The expression of β4GalT1 in glioma tissues was higher than that in normal tissues, and the higher the malignancy of the tumor, the higher the expression of β4GalT1 in the glioma tissues, and the lower the immune level was. The expression of IDH1, MGMT, and ki-67 was reduced, and the survival rate of the mice with glioma was improved after β4GalT1 was knocked down. In vitro tests, the activity of tumor cells and their reproductive ability can be reduced after β4GalT1 was knocked down, the immune level of the body can be improved, and the level of tissue apoptosis can be reduced. After recombinant β4GalT1 was given alone, the result was opposite to that of β4GalT1 knocked down group. In vivo tests, gross tumor volume can be reduced after β4GalT1 was knocked down, the immune level of the body can be improved, and the level of tissue apoptosis can be reduced. After recombinant β4GalT1 was given alone, the result was opposite to that of β4GalT1 knocked down group. After knocking down β4GalT1, the expression of inflammatory factors can be reduced both in vivo and in vitro, and the inflammatory microenvironment of tumors can be improved. After recombinant β4GalT1 was given alone, the result was opposite to that of β4GalT1 knocked down group.

CONCLUSIONS

The level of β4GalT1 expression in tumor tissues was increased. The malignant degree of glioma is related to the expression of β4GalT1 and its immunity. The level of tumor marker can be decreased, and the survival rate of glioma model mice can be increased after β4GalT1 is knocked down. Apoptosis and immune injury caused by tumor can be improved and gross tumor volume can be deduced after β4GalT1 is knocked down. During the development of glioma, β4GalT1 may play a malignant biological role through inflammatory response.